rs492594 — G6PC2 Val219Leu

G6PC2 Val219Leu — Tuning the Fasting Glucose Thermostat

Every morning, before you eat, your pancreatic beta cells are running a delicate balancing act. Glucokinase phosphorylates incoming glucose to glucose-6-phosphate, signaling the cell to release insulin. G6PC2 — expressed exclusively in beta cells — hydrolyzes that signal molecule back to glucose¹¹ hydrolyzes that signal molecule back to glucose
Hydrolysis of glucose-6-phosphate to glucose and phosphate in the endoplasmic reticulum, creating a futile substrate cycle. The tighter G6PC2 runs this cycle, the higher your fasting blood glucose must rise before the beta cell "sees" the glucose signal and releases insulin. This variant, rs492594, changes amino acid 219 in G6PC2 from valine (Val; G allele) to leucine (Leu; C allele), altering protein abundance and thereby adjusting how strongly this brake is applied.

The Mechanism

G6PC2 is a nine-transmembrane endoplasmic reticulum enzyme that directly opposes glucokinase — the primary beta-cell glucose sensor²² glucose sensor
Glucokinase phosphorylates glucose at a rate proportional to glucose concentration, making it the rate-limiting step for glucose-stimulated insulin secretion. The futile cycle they create wastes ATP but gives the beta cell a tunable sensitivity threshold. The Val219 form (G allele) of G6PC2 is the common enzyme variant and supports full baseline G6PC2 expression. The Leu219 form (C allele) shows reduced protein abundance via proteasomal degradation³³ reduced protein abundance via proteasomal degradation in cell-based experiments, effectively lowering the brake and allowing the beta cell to respond to glucose at a slightly lower concentration. Animal studies confirm this dose-response logic: complete deletion of G6pc2 in mice lowers fasting blood glucose by 14–16%⁴⁴ lowers fasting blood glucose by 14–16% without changing fasting insulin, because the beta cells now become sensitive at a lower glucose threshold — the insulin release curve shifts leftward.

Position 219 lies within a putative cholesterol recognition amino acid consensus (CRAC) motif⁵⁵ cholesterol recognition amino acid consensus (CRAC) motif
A transmembrane domain sequence that can interact with cholesterol; its presence suggests G6PC2 activity may be membrane-environment dependent. In detergent micelle experiments the Val219 and Leu219 forms show comparable enzymatic activity, but in intact microsomal membrane preparations — which better reflect the in vivo ER environment — the Leu219 variant has lower effective activity, consistent with the reduced protein abundance observed in cellular assays.

The Evidence

The definitive characterization of rs492594 as an independent fasting-glucose signal came from Mahajan et al. 2015⁶⁶ Mahajan et al. 2015
Identification and functional characterization of G6PC2 coding variants influencing glycemic traits define an effector transcript at the G6PC2-ABCB11 locus. PLoS Genetics, 2015, a study of up to 33,231 non-diabetic Europeans. After conditioning on the lead non-coding GWAS variant rs560887, three coding variants — including p.Val219Leu — each showed independent association with fasting glucose. Together they explained an additional 0.2% of phenotypic variance beyond rs560887, bringing the G6PC2 locus to ~1.1% of total fasting glucose variance.

A key haplotype complexity: the Leu219 C allele travels almost exclusively in cis with the glucose-raising G allele at rs560887. This means in population-level analyses the Leu219 allele appears to raise glucose (because rs560887-G dominates the haplotype effect), but conditional analysis and functional data confirm Leu219 is itself glucose-lowering through the protein abundance mechanism. In Asian populations, Hu et al. 2009⁷⁷ Hu et al. 2009
Hu C et al. A genetic variant of G6PC2 is associated with type 2 diabetes and fasting plasma glucose level in the Chinese population. Diabetologia, 2009 found rs492594 C allele nominally associated with higher fasting glucose (0.067 mmol/L per allele, p=0.04) in 3,676 subjects — likely reflecting this same haplotype linkage rather than the intrinsic coding-variant effect.

The broader G6PC2 locus signal (dominated by rs560887) is among the most robust common-variant associations with fasting glucose in the human genome, replicated in hundreds of thousands of individuals across multiple ethnicities⁸⁸ hundreds of thousands of individuals across multiple ethnicities with an effect of approximately +0.07 mmol/L per glucose-raising allele.

Practical Actions

The G6PC2 Val219Leu variant creates a modestly higher fasting glucose setpoint in Val219/Val219 (GG) carriers. The overall effect of this specific coding variant is small — on the order of 0.05–0.10 mmol/L per allele — and does not on its own meaningfully raise type 2 diabetes risk. However, fasting glucose sits on a continuum, and small chronic elevations contribute to cumulative glycemic burden over decades. For GG homozygotes, the most directly relevant interventions are those that lower fasting glucose through beta-cell glucose sensing: time-restricted eating (which lowers overnight fasting glucose), regular aerobic exercise (which upregulates skeletal muscle glucose uptake and lowers the glucose threshold needed for insulin release), and avoidance of late-evening carbohydrate loads that elevate glucose during the early fasting period.

Interactions

rs492594 sits at the same gene locus as rs560887, the strongest common-variant determinant of fasting glucose (~1% of FBG variance). The two variants are in partial linkage disequilibrium and have been shown to have conditionally independent effects. The non-coding rs560887 has a larger per-allele effect and should be interpreted alongside rs492594. The G6PC2 locus as a whole interacts additively with GCK variants (e.g. GCK rs1799884) and MTNR1B fasting glucose variants — individuals carrying risk alleles at multiple glycemic loci show compounded effects on fasting glucose and T2D risk. G6PC2 also interacts with glucokinase activity in the shared glucose-cycling substrate cycle; any factor that reduces glucokinase activity (e.g. GCK haploinsufficiency) amplifies the relative importance of G6PC2 in setting the fasting glucose threshold.